Recurrent Inversion Toggling and Great Ape Genome Evolution
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Investigation of Modifier Genes Within Copy Number Variations in Rett Syndrome
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/51147767 Investigation of modifier genes within copy number variations in Rett syndrome ARTICLE in JOURNAL OF HUMAN GENETICS · MAY 2011 Impact Factor: 2.53 · DOI: 10.1038/jhg.2011.50 · Source: PubMed CITATIONS DOWNLOADS VIEWS 6 89 134 15 AUTHORS, INCLUDING: Dag H Yasui Maria Antonietta Mencarelli University of California, Davis Azienda Ospedaliera Universitaria Senese 30 PUBLICATIONS 1,674 CITATIONS 58 PUBLICATIONS 962 CITATIONS SEE PROFILE SEE PROFILE Francesca Mari Janine M Lasalle Università degli Studi di Siena University of California, Davis 81 PUBLICATIONS 1,658 CITATIONS 98 PUBLICATIONS 3,525 CITATIONS SEE PROFILE SEE PROFILE Available from: Janine M Lasalle Retrieved on: 22 July 2015 Europe PMC Funders Group Author Manuscript J Hum Genet. Author manuscript; available in PMC 2012 January 01. Published in final edited form as: J Hum Genet. 2011 July ; 56(7): 508–515. doi:10.1038/jhg.2011.50. Europe PMC Funders Author Manuscripts Investigation of modifier genes within copy number variations in Rett syndrome Rosangela Artuso1,*, Filomena Tiziana Papa1,*, Elisa Grillo1, Mafalda Mucciolo1, Dag H. Yasui2, Keith W. Dunaway2, Vittoria Disciglio1, Maria Antonietta Mencarelli1, Marzia Pollazzon1, Michele Zappella3, Giuseppe Hayek4, Francesca Mari1, Alessandra Renieri1, Janine M. LaSalle2, and Francesca Ariani1 1 Medical Genetics Section, Biotechnology Department, University of Siena, Italy 2 Medical Microbiology and Immunology, Genome Center, School of Medicine, University of California, Davis, CA, USA 3 Child Neuropsychiatry, Versilia Hospital, Viareggio, Italy 4 Infantile Neuropsychiatry, Siena General Hospital, Italy Abstract MECP2 mutations are responsible for two different phenotypes in females, classical Rett syndrome and the milder Zappella variant (Z-RTT). -
The Set7 Lysine Methyltransferase Regulates Plasticity in Oxidative Phosphorylation Necessary for Trained Immunity Induced by Β-Glucan
University of Southern Denmark The Set7 Lysine Methyltransferase Regulates Plasticity in Oxidative Phosphorylation Necessary for Trained Immunity Induced by β-Glucan Keating, Samuel T.; Groh, Laszlo; van der Heijden, Charlotte D.C.C.; Rodriguez, Hanah; dos Santos, Jéssica C.; Fanucchi, Stephanie; Okabe, Jun; Kaipananickal, Harikrishnan; van Puffelen, Jelmer H.; Helder, Leonie; Noz, Marlies P.; Matzaraki, Vasiliki; Li, Yang; de Bree, L. Charlotte J.; Koeken, Valerie A.C.M.; Moorlag, Simone J.C.F.M.; Mourits, Vera P.; Domínguez-Andrés, Jorge; Oosting, Marije; Bulthuis, Elianne P.; Koopman, Werner J.H.; Mhlanga, Musa; El-Osta, Assam; Joosten, Leo A.B.; Netea, Mihai G.; Riksen, Niels P. Published in: Cell Reports DOI: 10.1016/j.celrep.2020.107548 Publication date: 2020 Document version: Final published version Document license: CC BY-NC-ND Citation for pulished version (APA): Keating, S. T., Groh, L., van der Heijden, C. D. C. C., Rodriguez, H., dos Santos, J. C., Fanucchi, S., Okabe, J., Kaipananickal, H., van Puffelen, J. H., Helder, L., Noz, M. P., Matzaraki, V., Li, Y., de Bree, L. C. J., Koeken, V. A. C. M., Moorlag, S. J. C. F. M., Mourits, V. P., Domínguez-Andrés, J., Oosting, M., ... Riksen, N. P. (2020). The Set7 Lysine Methyltransferase Regulates Plasticity in Oxidative Phosphorylation Necessary for Trained Immunity Induced by β-Glucan. Cell Reports, 31(3), [107548]. https://doi.org/10.1016/j.celrep.2020.107548 Go to publication entry in University of Southern Denmark's Research Portal Terms of use This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. -
Rationale for the Development of Alternative Forms of Androgen Deprivation Therapy
248 S Kumari, D Senapati et al. New approaches to inhibit 24:8 R275–R295 Review AR action Rationale for the development of alternative forms of androgen deprivation therapy Sangeeta Kumari1,*, Dhirodatta Senapati1,* and Hannelore V Heemers1,2,3 1Department of Cancer Biology, Cleveland Clinic, Cleveland, Ohio, USA Correspondence 2Department of Urology, Cleveland Clinic, Cleveland, Ohio, USA should be addressed 3Department of Hematology/Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA to H V Heemers *(S Kumari and D Senapati contributed equally to this work) Email [email protected] Abstract With few exceptions, the almost 30,000 prostate cancer deaths annually in the United Key Words States are due to failure of androgen deprivation therapy. Androgen deprivation f androgen receptor therapy prevents ligand-activation of the androgen receptor. Despite initial remission f prostate cancer after androgen deprivation therapy, prostate cancer almost invariably progresses while f nuclear receptor continuing to rely on androgen receptor action. Androgen receptor’s transcriptional f coregulator output, which ultimately controls prostate cancer behavior, is an alternative therapeutic f transcription target, but its molecular regulation is poorly understood. Recent insights in the molecular f castration mechanisms by which the androgen receptor controls transcription of its target genes f hormonal therapy are uncovering gene specificity as well as context-dependency. Heterogeneity in the Endocrine-Related Cancer Endocrine-Related androgen receptor’s transcriptional output is reflected both in its recruitment to diverse cognate DNA binding motifs and in its preferential interaction with associated pioneering factors, other secondary transcription factors and coregulators at those sites. This variability suggests that multiple, distinct modes of androgen receptor action that regulate diverse aspects of prostate cancer biology and contribute differentially to prostate cancer’s clinical progression are active simultaneously in prostate cancer cells. -
3073.Full.Pdf
ORIGINAL ARTICLE Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes Anna Syreeni,1 Assam El-Osta,2 Carol Forsblom,1,3 Niina Sandholm,1 Maikki Parkkonen,1 Lise Tarnow,4 Hans-Henrik Parving,5 Amy J. McKnight,6 Alexander P. Maxwell,6 Mark E. Cooper,2 and Per-Henrik Groop,1,2,3 on behalf of the FinnDiane Study Group OBJECTIVE—Hyperglycemia plays a pivotal role in the de- velopment and progression of vascular complications, which are the major sources of morbidity and mortality in diabetes. icro- and macrovascular complications develop Furthermore, these vascular complications often persist and in a subset of individuals with type 1 diabetes. progress despite improved glucose control, possibly as a result of The severity of comorbid complications is es- fi prior episodes of hyperglycemia. Epigenetic modi cations mediated pecially striking in patients with established by histone methyltransferases are associated with gene-activating M events that promote enhanced expression of key proinflammatory diabetic nephropathy, who have an 18.3-fold increased all- molecules implicated in vascular injury. In this study, we inves- cause mortality rate when compared with the general pop- tigated genetic polymorphisms of the SETD7, SUV39H1, and ulation (1). Diabetic nephropathy clusters in families (2), SUV39H2 methyltransferases as predictors of risk for micro- and which emphasizes the importance of an inherited genetic macrovascular complications in type 1 diabetes. component. Diabetic retinopathy is another microvascular — complication that has an inherited susceptibility (herita- RESEARCH DESIGN AND METHODS In the Finnish Di- h2 abetic Nephropathy Study (FinnDiane) cohort, 37 tagging single bility of = 0.52 in the Finnish population) (3). -
A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context. -
Epigenetic Services Citations
Active Motif Epigenetic Services Publications The papers below contain data generated by Active Motif’s Epigenetic Services team. To learn more about our services, please give us a call or visit us at www.activemotif.com/services. Technique Target Journal Year Reference Justin C. Boucher et al. CD28 Costimulatory Domain- ATAC-Seq, Cancer Immunol. Targeted Mutations Enhance Chimeric Antigen Receptor — 2021 RNA-Seq Res. T-cell Function. Cancer Immunol. Res. doi: 10.1158/2326- 6066.CIR-20-0253. Satvik Mareedu et al. Sarcolipin haploinsufficiency Am. J. Physiol. prevents dystrophic cardiomyopathy in mdx mice. RNA-Seq — Heart Circ. 2021 Am J Physiol Heart Circ Physiol. doi: 10.1152/ Physiol. ajpheart.00601.2020. Gabi Schutzius et al. BET bromodomain inhibitors regulate Nature Chemical ChIP-Seq BRD4 2021 keratinocyte plasticity. Nat. Chem. Biol. doi: 10.1038/ Biology s41589-020-00716-z. Siyun Wang et al. cMET promotes metastasis and ChIP-qPCR FOXO3 J. Cell Physiol. 2021 epithelial-mesenchymal transition in colorectal carcinoma by repressing RKIP. J. Cell Physiol. doi: 10.1002/jcp.30142. Sonia Iyer et al. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of ATAC-Seq — Cancer Discovery 2021 Combination Immunotherapy. Cancer Discov. doi: doi: 10.1158/2159-8290 Vinod Krishna et al. Integration of the Transcriptome and Genome-Wide Landscape of BRD2 and BRD4 Binding BRD2, BRD4, RNA Motifs Identifies Key Superenhancer Genes and Reveals ChIP-Seq J. Immunol. 2021 Pol II the Mechanism of Bet Inhibitor Action in Rheumatoid Arthritis Synovial Fibroblasts. J. Immunol. doi: doi: 10.4049/ jimmunol.2000286. Daniel Haag et al. -
In-Silico Discovery of Cancer-Specific Peptide-HLA Complexes for Targeted Therapy Ankur Dhanik*, Jessica R
Dhanik et al. BMC Bioinformatics (2016) 17:286 DOI 10.1186/s12859-016-1150-2 RESEARCH ARTICLE Open Access In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy Ankur Dhanik*, Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Hsin C. Lin, Andrew J. Murphy and Wen Zhang Abstract Background: Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to peptide fragments of proteins degraded inside the cell and display them on the cell surface. We are interested in peptide-HLA complexes involving peptides that are derived from proteins specifically expressed in cancer cells. Such complexes have been shown to provide an effective means of precisely targeting cancer cells by engineered T-cells and antibodies, which would be an improvement over current chemotherapeutic agents that indiscriminately kill proliferating cells. An important concern with the targeting of peptide-HLA complexes is off-target toxicity that could occur due to the presence of complexes similar to the target complex in cells from essential, normal tissues. Results: We developed a novel computational strategy for identifying potential peptide-HLA cancer targets and evaluating the likelihood of off-target toxicity associated with these targets. Our strategy combines sequence-based and structure-based approaches in a unique way to predict potential off-targets. The focus of our work is on the complexes involving the most frequent HLA class I allele HLA-A*02:01. Using our strategy, we predicted the off-target toxicity observed in past clinical trials. We employed it to perform a first-ever comprehensive exploration of the human peptidome to identify cancer-specific targets utilizing gene expression data from TCGA (The Cancer Genome Atlas) and GTEx (Gene Tissue Expression), and structural data from PDB (Protein Data Bank). -
The Human Canonical Core Histone Catalogue David Miguel Susano Pinto*, Andrew Flaus*,†
bioRxiv preprint doi: https://doi.org/10.1101/720235; this version posted July 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. The Human Canonical Core Histone Catalogue David Miguel Susano Pinto*, Andrew Flaus*,† Abstract Core histone proteins H2A, H2B, H3, and H4 are encoded by a large family of genes dis- tributed across the human genome. Canonical core histones contribute the majority of proteins to bulk chromatin packaging, and are encoded in 4 clusters by 65 coding genes comprising 17 for H2A, 18 for H2B, 15 for H3, and 15 for H4, along with at least 17 total pseudogenes. The canonical core histone genes display coding variation that gives rise to 11 H2A, 15 H2B, 4 H3, and 2 H4 unique protein isoforms. Although histone proteins are highly conserved overall, these isoforms represent a surprising and seldom recognised variation with amino acid identity as low as 77 % between canonical histone proteins of the same type. The gene sequence and protein isoform diversity also exceeds com- monly used subtype designations such as H2A.1 and H3.1, and exists in parallel with the well-known specialisation of variant histone proteins. RNA sequencing of histone transcripts shows evidence for differential expression of histone genes but the functional significance of this variation has not yet been investigated. To assist understanding of the implications of histone gene and protein diversity we have catalogued the entire human canonical core histone gene and protein complement. -
View a Copy of This Licence, Visit
Robertson et al. BMC Biology (2020) 18:103 https://doi.org/10.1186/s12915-020-00826-z RESEARCH ARTICLE Open Access Large-scale discovery of male reproductive tract-specific genes through analysis of RNA-seq datasets Matthew J. Robertson1,2, Katarzyna Kent3,4,5, Nathan Tharp3,4,5, Kaori Nozawa3,5, Laura Dean3,4,5, Michelle Mathew3,4,5, Sandra L. Grimm2,6, Zhifeng Yu3,5, Christine Légaré7,8, Yoshitaka Fujihara3,5,9,10, Masahito Ikawa9, Robert Sullivan7,8, Cristian Coarfa1,2,6*, Martin M. Matzuk1,3,5,6 and Thomas X. Garcia3,4,5* Abstract Background: The development of a safe, effective, reversible, non-hormonal contraceptive method for men has been an ongoing effort for the past few decades. However, despite significant progress on elucidating the function of key proteins involved in reproduction, understanding male reproductive physiology is limited by incomplete information on the genes expressed in reproductive tissues, and no contraceptive targets have so far reached clinical trials. To advance product development, further identification of novel reproductive tract-specific genes leading to potentially druggable protein targets is imperative. Results: In this study, we expand on previous single tissue, single species studies by integrating analysis of publicly available human and mouse RNA-seq datasets whose initial published purpose was not focused on identifying male reproductive tract-specific targets. We also incorporate analysis of additional newly acquired human and mouse testis and epididymis samples to increase the number of targets identified. We detected a combined total of 1178 genes for which no previous evidence of male reproductive tract-specific expression was annotated, many of which are potentially druggable targets. -
Bioinformatic Pipeline for Whole Exome Sequence (WES) Analysis
SUPPLEMENT Supplement contents: Supplementary Methods Supplementary Figure 1: Bioinformatic pipeline for whole exome sequence (WES) analysis. Supplementary Figure 2: Pedigrees and HomozygosityMapper output for families with single variants identified, in addition to those shown in Figure 2. Supplementary Figure 3: Spatiotemporal expression of ID genes in human development using RNA sequencing data. Supplementary Figure 4: Developmental expression pattern of ID genes in the human prefrontal cortex. Supplementary Table 1: Family statistics Supplementary Table 2: Homozygosity-by-descent/autozygosity shared regions, as defined using HomozygosityMapper, cross-referenced with FSuite. Supplementary Table 3: Mutations identified per family. A. Single homozygous variant identified. B. Two to four variants identified. C. Dominant/de novo mutation identified. Supplementary Table 4: Pathogenic CNVs and variants of unknown significance identified by microarray analysis. Supplementary Table 5: BioGRID protein interaction and gene ontology analysis. (separate Excel file) Supplementary Table 6: Gene Ontology Pathway analysis. Supplementary Table 7: Gene List for anatomic/temporal transcription analyses. Supplementary Table 8: Top anatomical regions for ID gene expression. Supplementary Methods HBD/Autozygosity mapping Both of the below methods and the hg19 version of the genome were used to ensure a consistent and uniform genotyping. Genotyping data was uploaded to the HomozygosityMapper server to determine putative homozygous-by- descent (HBD) regions based on the allele frequencies of the markers uploaded to the server from previous studies. HBD regions were identified by manual curation and only HBD regions larger than 1 Mb shared between all affected members (and not unaffected members) of the family were chosen. These regions were extracted based on SNP RS numbers and these dbSNP identifiers were converted to a genomic position for used to represent genomic regions with NGS data. -
SETD7 Is Promising Druggable Target for Treating
Sequence and Pathway analysis SETD7 is promising druggable target for treating Lung Neoplasms that controls activity of CTCF, NR3C1 and TCF7L2 transcription factor on promoters of genes encoding enzymes metabolizing given metabolites Demo User geneXplain GmbH [email protected] Data received on 06/09/2019 ; Run on 31/10/2020 ; Report generated on 31/10/2020 Genome Enhancer release 2.2 (TRANSFAC®, TRANSPATH® and HumanPSD™ release 2020.3) Abstract In the present study we applied the software package "Genome Enhancer" to a data set that contains metabolomics data. The study is done in the context of Lung Neoplasms. The goal of this pipeline is to identify potential drug targets in the molecular network that governs the studied pathological process. In the first step of analysis pipeline discovers transcription factors (TFs) that regulate genes activities in the pathological state. The activities of these TFs are controlled by so- called master regulators, which are identified in the second step of analysis. After a subsequent druggability checkup, the most promising master regulators are chosen as potential drug targets for the analyzed pathology. At the end the pipeline comes up with (a) a list of known drugs and (b) investigational active chemical compounds with the potential to interact with selected drug targets. From the data set analyzed in this study, we found the following TFs to be potentially involved in the regulation of the genes encoding enzymes metabolizing given metabolites: CTCF, NR3C1 and TCF7L2. The subsequent network analysis suggested setd7 SUV39H1 as the most promising molecular targets for further research, drug development and drug repurposing initiatives on the basis of identified molecular mechanism of the studied pathology. -
Anti-SETD7 (Aa 50-150) Polyclonal Antibody (DPABH-04287) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
Anti-SETD7 (aa 50-150) polyclonal antibody (DPABH-04287) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Histone methyltransferase that specifically monomethylates Lys-4 of histone H3. H3 Lys-4 methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in the transcriptional activation of genes such as collagenase or insulin. Recruited by IPF1/PDX- 1 to the insulin promoter, leading to activate transcription. Has also methyltransferase activity toward non-histone proteins such as p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins. Monomethylates Lys-189 of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II. Monomethylates Lys-372 of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation. Also able to demethylated Lys-372 of p53/TP53 in vitro. Immunogen Synthetic peptide conjugated to KLH derived from within residues 50 - 150 of Human SETD7. Isotype IgG Source/Host Rabbit Species Reactivity Rat, Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB Format Liquid Size 100 μg Buffer pH: 7.40; Constituent: PBS. Note: Batches of this product that have a concentration Preservative 0.02% Sodium Azide Storage Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. GENE INFORMATION 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected]